Strata Skin Sciences this week announced that it signed a distribution agreement with JuvenIL to supply Strata’s Xtrac excimer lasers in Israel.
Israel-based JuvenIL makes dermatology and aesthetic technologies for medical centers across the country. The distribution deal will provide Strata Skin Sciences with a similar distribution network.
“We believe that entering into the Israeli market presents a good opportunity for Strata,” president and CEO Robert Moccia said in a news release. “Following approval to market our products in Israel, we identified JuvenIL as the ideal partner in the region. Through JuvenIL, we can now market our products to the entire Israeli population, of which there are an estimated 300,000 psoriasis and 160,000 vitiligo patients that can benefit from our laser treatment. We are confident that JuvenIL’s experienced team will be invaluable as they work with the more than forty major hospitals and four major Health Maintenance Organizations in Israel to commercialize Strata’s Xtrac excimer lasers.”
Strata Skin Sciences acquired the Xtrac laser technologies from Ra Medical in 2021 as part of its Pharos dermatology business acquisition. The excimer laser system is FDA cleared to treat chronic skin diseases, including psoriasis, vitiligo, atopic dermatitis and leukoderma.